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Mesenchymal stem or stromal cells (MSCs) have many potential
therapeutic applications including therapies for cancers and tissue
damages caused by cancers or radical cancer treatments. However,
tissue-derived MSCs such as bone marrow MSCs (BM-MSCs) may
promote cancer progression and have considerable donor varia-
tions and limited expandability. These issues hinder the potential
applications of MSCs, especially those in cancer patients. To cir-
cumvent these issues, we derived MSCs from transgene-free
human induced pluripotent stem cells (iPSCs) efficiently with a mod-
ified protocol that eliminated the need of flow cytometric sorting.
Our iPSC-derived MSCs were readily expandable, but still underwent
senescence after prolonged culture and did not form teratomas.
These iPSC-derived MSCs homed to cancers with efficiencies similar
to BM-MSCs but were much less prone than BM-MSCs to promote
the epithelial–mesenchymal transition, invasion, stemness, and
growth of cancer cells. The observations were probably explained
by the much lower expression of receptors for interleukin-1 and
TGFβ, downstream protumor factors, and hyaluronan and its cofac-
tor TSG6, which all contribute to the protumor effects of BM-MSCs.
The data suggest that iPSC-derivedMSCs preparedwith themodified
protocol are a safer and better alternative to BM-MSCs for thera-
peutic applications in cancer patients. The protocol is scalable
and can be used to prepare the large number of cells required
for “off-the-shelf” therapies and bioengineering applications.
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protumor effects
The use of mesenchymal stromal or stem cells (MSCs) incancer patients or cancer survivors is a promising strategy to
improve treatment of advanced cancer (1) and to repair tissues
damaged by cancers or by radical cancer therapies (2). Based on
the unique homing capability of tissue-derived MSCs to stroma
of various primary and metastatic cancers (3–6), MSCs have the
potential to treat or even eliminate various cancers by delivering
various anticancer agents (7–9). Because of their potential for
differentiation (10, 11) and production of immunomodulatory,
angiogenic, anti-apoptotic, anti-scarring, and prosurvival factors
(12), MSCs have shown promising regeneration potential after
radical cancer treatment in animal models, such as soft tissue
reconstruction after disfiguring surgeries for head, neck, or
breast cancers (13) and salivary gland regeneration for head and
neck cancer patients treated with radiotherapy (14, 15). As one
example, the combination of osteogenic potential and targeted
delivery of anticancer agents make MSCs a promising option
to treat tumor-induced osteolysis (16, 17). However, exogenous
tissue-derived MSCs, including those from bone marrow, adi-
pose tissues, and umbilical cord, have all shown a tendency to
promote rather than inhibit cancers in many circumstances (18–
23). Also, endogenous MSCs are a major source of reactive
stromal cells that promote growth and metastasis of cancers (4, 24).
Moreover, MSCs have a limited proliferation potential and
lose some of their important biological functions as they are
expanded (25). Therefore, it is difficult to prepare large banks of
the cells with uniform biological activities and/or transgene ex-
pression required for experiments in large animals and for po-
tential clinical therapies. Another problem is that MSCs are
being prepared with a variety of protocols in different labora-
tories from different donors. As a result, standardization of the
cells has been extremely difficult and the data presented in dif-
ferent publications are difficult to compare. Hence large banks
of reference cells are needed to advance the MSC research (26).
To address the limitations of expandability and standardiza-
tion, we derived MSCs from induced pluripotent stem cells
(iPSCs) with a modified protocol that can be expanded to pro-
vide large cell banks from a single cell clone. The protocol
produces highly enriched MSC-like cells from iPSCs with high
efficiency. The iPSC-derived MSCs (iPSC-MSCs) express the
classical surface markers of MSCs, are capable of multilineage
mesodermal differentiation and cancer homing, and can be
expanded extensively, but do not preserve the pluoripotency
of iPSCs. Surprisingly, iPSC-MSCs do not promote epithelial–
mesenchymal transition (EMT), invasion, and stemness of can-
cer cells as is seen with bone marrow-derived MSCs (BM-MSCs).
Consistent with these observations, the iPSC-MSCs express
much lower levels than BM-MSCs of protumor factors including
interleukine-6, prostaglandin E2, SDF1, and hyaluronan before
and after exposure to tumor microenvironment. Our data in-
dicated that iPSC-MSCs are a safe alternative to BM-MSCs for
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cancer therapy and other applications with better expandability
and potential for genetic engineering.
Results
Derivation of MSC-Like Cells from Human iPS Cells. Sánchez et al.
(27) reported that inhibition of SMAD-2/3 signaling promoted
derivation of MSCs from human embryonic stem cells (ESCs) but
not from human iPSCs. To derive MSCs efficiently from human
iPSCs, we modified their method by using chemically defined
mTeSR1 medium (28) supplemented with the SMAD-2/3 inhibitor
(SB-431542) and an atmosphere of 7.5% CO2 (29) to culture
colonies of cells on Matrigel-coated plates. The cells were passaged
at 80–90% confluency by lifting with Dispase. After about 25 d,
most cells became larger with increased cytoplasm, and cells at the
edge of the cell cluster became spindle-shaped, suggesting spon-
taneous differentiation (Fig. 1A). We then digested the cultures
with trypsin to generate suspensions of single cells and transferred
them to standard tissue culture plates. The cells were incubated in
ESC–MSC medium (30) containing SB-431542, lifted at 80–90%
confluency by trypsin about every 3 d, diluted 1:3, and passaged
repeatedly under the same conditions (4431). During repeated
passaging by trypsinization, more and more adherent cells gradu-
ally showed spindle-like morphology and appeared in whorls sim-
ilar to MSCs and fibroblasts (Fig. 1A). After 45 d, quantitative RT-
PCR (qRT-PCR) analysis indicated there was a marked decrease
in the expression of the pluripotent genes Nanog and Oct4, the
neuroectoderm marker Ecad, and the endoderm marker Foxa2 in
the adherent cells. In contrast, there was a marked increase in the
expression of the mesodermal marker CD140A/Pdgfra (Fig. 1B, P <
0.001). Flow cytometric analysis indicated that, similar to BM-
MSCs, positive MSC markers were expressed by the vast majority
of adherent cells (>99.6% for CD73, CD105, and CD166, and
>88.4% for CD44 and CD90), whereas negative MSC markers
including HLA-DR, CD11b, CD24, CD34, and CD45 were
expressed by a very small fraction of these cells (<4.1%, Fig. 1C).
When incubated in standard osteogenic media, the adherent cells
were remarkably osteogenic, generating a fully differentiated
monolayer of mineralizing MSCs within 10 d, about half of the
time required for BM-MSCs (Fig. 1D). The adherent cells also
generated cartilage in micromass cultures in the presence of both
BMP2 and TGFβ (Fig. 1D). In contrast, when the cells were ex-
posed to routine adipogenic conditions for a standard duration of
20 d, they were modestly responsive compared with BM-MSCs
(Fig. 1D). qRT-PCR analysis indicated that in iPSC-MSCs the up-
regulation of most markers for osteoblasts or chondrocytes after
corresponding differentiation was significantly higher, whereas the
up-regulation of most adipogenic markers was significantly lower
compared with BM-MSCs (Fig. 1E). Because the adherent cells
met the standard criteria of MSCs (32), they were subsequently
referred to as iPSC-MSCs and designated as passage 0. As ex-
pected, telomerase activity in iPSC-MSCs was much higher than
that in BM-MSCs (passage 4) but much lower than that in parent
iPSCs (passage 39) (Fig. 1F). Consequently, the colony-forming
unit–fibroblast (CFU–F)-forming efficiency of iPSC-MSCs was also
much higher than that of BM-MSCs at passages 4 and 12 (Fig. 1G),
indicating better expandability of iPSC-MSCs compared with BM-
MSCs. The average population doubling time from passages 3–15
for iPSC-MSCs was significantly shorter than that of BM-MSCs
(25.28 ± 2.92 vs. 33.91 ± 5.03 h, mean ± SEM, n = 3, P < 0.05),
indicating that iPSC-MSCs propagate more rapidly than BM-
MSCs. However, iPSC-MSCs were not immortal in culture. They
underwent senescence and could not be expanded beyond 17
passages (64 population doublings), similar to BM-MSCs cultured
under the same conditions that underwent senescence after 16
passages (48 population doublings) (Fig. 1H). Cytogenetic analysis
indicated that iPSC-MSCs at passage 7 had a normal karyotype
(Fig. S1), and no teratoma formation was observed in non-obese
diabetic (NOD)/SCID mice inoculated with iPSC-MSCs after
4 mo. The data indicated therefore that we have developed an
efficient and safe protocol to derive MSCs from human iPSCs.
Human iPSC-MSCs Were Capable of Homing to Tumors. MSCs from
various tissues have a unique tumor-homing capacity that enables
them to serve as vehicles for gene therapy of advanced cancers.
The tumor tropism of these MSCs is mediated by multiple che-
mokine receptors such as CXCR4 and CXCR6 (4–6), CD44 (33),
and VEGFR1 (3) and integrins such as ITGA6 and ITGB1 (34, 35).
The expression of VEGFR1 was dramatically higher in iPSC-MSCs
than in BM-MSCs, whereas the expression of other homing-related
genes was comparable between iPSC-MSCs and BM-MSCs (Fig.
2A). In vitro transwell migration experiments showed that there
was significantly increased migration of BM-MSCs to MDA-
MB231 cells, a line of triple-negative human breast cancer cells,
compared with control human embryonic kidney 293T cells.
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Fig. 1. Characterization of iPSC-MSCs. (A) Derivation
and morphology of MSC-like cells from human iPSCs.
(B) qRT-PCR analysis of relative expression of marker
genes for pluripotency and each germ layer in iPSCs,
BM-MSCs, and iPSC-MSCs (**P < 0.01 vs. iPSCs; ND, not
detected). (C) Flow cytometry analysis of surface
markers in iPSC-MSCs. (D and E) Multilineage differ-
entiation of iPSC-MSCs. After 2 wk of corresponding
induction, differentiated iPSC-MSCs were stained for
mineralization with Alizarin Red, for chondrocytes
with Toluidine Blue, or for lipid drops with Oil Red,
respectively (D), and analyzed for expression of marker
genes of osteoblasts, chondrocytes, or adipocytes, re-
spectively, by qRT-PCR in comparison with identically
differentiated BM-MSCs (E). (F) Telomerase activities in
iPSCs, BM-MSCs, and iPSC-MSCs. (G) CFU–F-forming as-
say. *P < 0.05. (H) Growth curves of BM-MSCs and
iPSC-MSCs (n = 3). iPSC-MSCs ceased expanding after
17 passages (64 population doublings) and BM-MSCs
after 16 passages (48 population doublings).
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Similar results were reported previously (8). The migration of
iPSC-MSCs to MDA-MB231 cells was similarly significantly in-
creased compared with that of 293T cells or medium alone (Fig.
2B, P < 0.01), and was comparable to that of BM-MSCs to
the MDA-MB231 cells (P > 0.1). To confirm the in vivo tumor
tropism of iPSC-MSCs, we generated human cancer xenograft
models of LoVo colorectal cancer cells and MDA-MB231 breast
cancer cells. After tumor establishment, BM-MSCs or iPSC-MSCs
transduced with CMV-copGFP lentivirus were injected into
tumor-bearing mice intravenously. To quantify the homing of MSCs
to cancer, we developed individual standard curves of CMV qPCR
for BM-MSCs or iPSC-MSCs carrying CMV-copGFP by adding
varying amounts of genomic DNA (gDNA) from corresponding
cells to gDNAs of LoVo or MDA-MB-231 tumor tissues from
mice without infusion of MSCs (Fig. 2C, R2 > 0.97). Sixteen hours
after MSC infusion, qPCR of CMV promoter sequence indicated
that infused BM-MSCs and iPSC-MSCs homed to LoVo or MDA-
MB-231 tumors with comparable efficiencies (Fig. 2 D and E, P >
0.05). Consistent with these observations, GFP+ cells were found in
sections of LoVo or MDA-MB-231 tumor samples from mice in-
fused with BM-MSCs or iPSC-MSCs carrying CMV-copGFP (Fig.
2F). Taken together, these data indicated that iPSC-MSCs are
capable of homing to cancer similarly to BM-MSCs.
iPSC-MSCs Had Less Potential than BM-MSCs to Promote Epithelial–
Mesenchymal Transition, Invasion, and Cancer Stem Cell Expansion.
Interactions between carcinoma cells and MSCs promote me-
tastasis and/or expansion of the cancer stem cells by enhancing
EMT (19). We first compared the potential of iPSC-MSCs and
BM-MSCs to enhance EMT of cocultured cancer cells. Cancer
cells were transduced with CMV-copGFP lentiviruses, cocul-
tured with MSCs, and then sorted by FACS. In LoVo cancer
cells, 12 h of cocultures with BM-MSCs significantly decreased
the expression of the epithelial maker E-cadherin (ECAD) and
significantly increased expression of mesenchymal makers fibro-
nectin1 (FN1), N-cadherin (NCAD), vimentin (VIM), and metallo-
proteinase 2 (MMP2) as well as the pro-EMT factors ZEB1,
ZEB2, and TWIST1 (Fig. 3A). In contrast, coculture with iPSC-
MSCs did not significantly decrease expression of ECAD and
had either no significant effects on or produced much smaller
increases of the expression of these mesenchymal markers or
pro-EMT genes in LoVo cells (Fig. 3A). The results demon-
strated therefore that the iPSC-MSCs had less potential to
promote EMT than BM-MSCs. To determine whether the iPSC-
MSCs promoted invasion of cancer cells, an invasion assay using
collagen IV-coated Boyden chambers was used. After coculture
with BM-MSCs for 3 d, invasion of LoVo, HCC1806, and MCF7
human cancer cells was significantly increased (Fig. 3B, P <
0.05). In contrast, there was no significant increase after co-
culture with iPSC-MSCs (Fig. 3B, P > 0.05). To test whether the
iPSC-MSCs promoted expansion of cancer stem cells (CSCs), we
examined the aldehyde dehydrogenase (ALDH)+ population in
LoVo colorectal cancer cells that are enriched for CSCs (19).
After coculture with BM-MSCs for 5 d, there was significant
expansion of the ALDH+ cells (Fig. 3C). Coculture with iPSC-
MSCs had no significant effect. Similar effects of iPSC-MSCs on
expression of EMT-related genes and ALDH+ population were
observed in HCC1806, another line of human triple-negative
breast cancer cells (Fig. S2). Consistent results were obtained
with another assay for cancer stem cells: the mammosphere-
forming capacity that is characteristic of breast cancer stem cells
in cultures of MCF7 and HCC1806 cells (36). After coculture for
3 d, mammosphere formation of FACS-isolated breast cancer
cells was significantly increased by BM-MSCs but not by iPSC-
MSCs (Fig. 3D). Coinoculation with BM-MSCs remarkably in-
creased the tumor-initiating ability and the tumor growth of
multiple types of cancer cells including HCC1806 (19); however,
we found that the tumor-initiating ability and the weights of
tumors of HCC1806 cells coinoculated with iPSC-MSCs were
significantly lower than those coinoculated with BM-MSCs when
either 5 × 104 or 5 × 103 HCC1806 cancer cells were injected
(P < 0.05 for tumor weight, Fig. 3E). Collectively, these data
indicated that our iPSC-MSCs are less prone to support the
growth and invasion of cancers than BM-MSCs.
Activity of IL1R-PGE2-IL6 Pathway Was Marginal in iPSC-MSCs. For
cancer cells such as LoVo and HCC1806 that express a high level
of interleukin-1 (IL1), the protumor effect of MSCs is mediated
mainly by the IL1 receptor (IL1R)/prostaglandin E2 (PGE2)
pathway (19). Our iPSC-MSCs compared with BM-MSCs expressed
much lower levels of mRNA for IL1R type 1 (IL1R1), the signal
transducer of IL1 pathway (37), and prostaglandin E synthase
(PTGES/mPGES1). The much lower levels of expression of
these two genes were not significantly affected by treatment
with 0.25 ng/mL IL1β, tumor-conditioned medium (TCM) from
LoVo cells or coculture with LoVo cells (Fig. 4A). The basal level
of expression of cyclooxygenase-2 (Cox2/PTGS2), another key
PGE2 synthase, was about the same in BM-MSCs and iPSC-MSCs
cultured in αMEM, but there was less up-regulation of Cox2 in
iPSC-MSCs than in BM-MSCs after treatment with IL1 or LoVo
TCM or coculture with LoVo cells (Fig. 4A, P < 0.05). As expected
from these observations, the level of PGE2 in the medium of
iPSC-MSCs was lower than that in BM-MSCs after treatment with
IL1, LoVo TCM, or LoVo cells (Fig. 4B, P < 0.01). As a conse-
quence, the expression of Interleukin-6 (IL6), a major protumor
factor regulated by both IL1 and PGE2, was much lower in
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Fig. 2. The tumor tropism of iPSC-MSCs. (A) qRT-PCR analysis of genes related to tumor homing in MSCs. (B) In vitro migration of MSCs toward 293T or
MDA-MB-231 cells in transwells. (C) Standard curve for qPCR assays of MSCs carrying CMV-copGFP added into LoVo or MDA-MB-231 cancer xenografts. Values
indicate ΔCt for primers for CMV promoter and mouse/human GAPDH genes on same samples; n = 3. (D and E) Estimated percentage of homed MSCs carrying
CMV-copGFP in all tumor cells in the LoVo or MDA-MB-231 cancer xenograft model based on qPCR of CMV promoter; n = 5. (F) Homing of i.v. infused
GFP-MSCs to established s.c. LoVo or MDA-MB-231 cancer xenografts was confirmed by immunofluorescence staining of copGFP in frozen sections.
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iPSC-MSCs than in BM-MSCs under all culture conditions (Fig.
4A, P < 0.05). These data indicate that the iPSC-MSCs are in-
sensitive to IL1 and hence have much less potential than BM-MSCs
to promote the growth and invasion of IL1-expressing cancer cells.
TGFβ Signaling and Production of Related Protumor Factors Was Less
in iPSC-MSCs than in BM-MSCs. TGFβ signaling is also essential for
the protumor effects of BM-MSCs. It increases expression of
multiple protumor factors such as stromal cell-derived factor 1
(SDF1/CXCL12), plasminogen activator inhibitor type 1 (PAI1/
SERPINE1), and IL6 (4, 38, 39). When cultured in αMEM or
TCM from MDA-MB-231 cancer cells or treated with 1 ng/mL
TGFβ1, iPSC-MSCs expressed lower levels than BM-MSCs of
the TGFβ receptor type 2 (TGFBR2) and of the TGFβ target
genes inhibitor of differentiation 3 (ID3) (40), IL6, and SDF1 (P <
0.05, Fig. 5A). The expression of TGFβ receptor type 1 (TGFBR1)
was not significantly different between these two types of MSCs
cultured in αMEM or TCM, but was significantly lower in iPSC-
MSCs than in BM-MSCs when both cells were treated with TGFβ1
(P < 0.05, Fig. 5A). The expression of PAI1, another TGFβ target
gene (41) with protumor activities, was not significantly different
between these two types of MSCs cultured in αMEM, but was
significantly lower in iPSC-MSCs than in BM-MSCs when
treated with TCM or TGFβ1 (P < 0.05, Fig. 5A). Western blot
analysis confirmed that the level of phospho-Smad3 was signifi-
cantly lower in iPSC-MSCs than in BM-MSCs when cultured in
αMEM or TCM or treated with TGFβ1, whereas the level of
phospho-Smad2 was undetectable in both MSCs cultured in
αMEM or TCM but was significantly lower in iPSC-MSCs than
in BM-MSCs when treated with TGFβ1 (P < 0.05, Fig. 5B).
These data indicate that decreased TGFβ signaling also con-
tributes to the lack of significant protumor effects in iPSC-MSCs.
iPSC-MSCs Compared with BM-MSCs Produced Less Hyaluronan and
TSG6 and Did Not Up-Regulate Lysyl Oxidase in Cocultures with
Cancer Cells. One essential mechanism of the protumor effects
of BM-MSCs is the up-regulation of lysyl oxidase (LOX) in ad-
jacent cancer cells by triggering the CD44-signaling pathway with
hyaluronan (HA) to promote EMT and metastasis (42). Tumor
necrosis factor α-induced protein 6 (TSG6), a secreted protein
highly expressed by BM-MSCs (43), enhances or induces the
binding of HA to cell-surface CD44 (44). In iPSC-MSCs, the
expression of TSG6 and dominant HA synthases (HAS1 and
HAS2) was dramatically lower than that in BM-MSCs with or
without coculture with LoVo cancer cells (Fig. 6A, P < 0.01).
Consistent with this observation, the amount of HA secreted into
medium by iPSC-MSCs was significantly lower than by BM-
MSCs at passages 5 and 15 (Fig. 6B, P < 0.01). As expected, in
cocultures with HCC1806 or LoVo cancer cells, iPSC-MSCs were
less effective than BM-MSCs in up-regulating the LOX mRNA in
cancer cells (Fig. 6C, P < 0.01). Therefore, the results indicated that
decreased up-regulation of LOX contributes to the lack of signifi-
cant pro-EMT and proinvasion effects of iPSC-MSCs.
Discussion
The differentiation of human iPSCs to MSCs has been reported to
be much less efficient than the differentiation of ESCs to MSCs (20
vs. 40% CD73+) (27). Also, flow cytometric sorting is generally
necessary to isolate iPSC-derived MSCs, a procedure that is ex-
pensive, technically challenging, and may cause damage to cells. We
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modified the differentiation protocol by initially inhibiting Smad2/3
signaling in iPSCs cultured with chemically defined mTeSR1 me-
dium (28) and then passaging cells by trypsinization (31) repeatedly
(30) in 7.5% CO2 (29), conditions that were previously reported to
improve the differentiation toward MSCs. During the repeated
passaging by trypsinization, we used standard tissue culture plastic
dishes instead of gelatin-coated plates. The early introduction of the
tissue culture plastic dishes probably accelerated selection for MSC-
like cells because the dishes are pretreated under proprietary con-
ditions to increase oxygenated derivatives on the surface of the
plastic and thereby make them more hydrophilic and increase the
adherence of vertebrate fibroblasts and similar cells (45). The se-
lection by adherence on the treated plastic also met one of the
minimal defining criteria for human MSCs (32). This modified
protocol achieved highly efficient enrichment of iPSC-MSCs
(>99.6% were positive for CD73, CD105, and CD166) and elimi-
nated the need of flow cytometric sorting. The iPSC-MSCs ex-
panded more rapidly and to a greater extent than BM-MSCs,
but still eventually underwent senescence similar to BM-MSCs.
Therefore, they were less likely to cause tumors or malignan-
cies in patients than cells that are immortal in culture (46). Also,
the iPSC-MSCs did not form teratomas in mice.
The immunosuppressive, anti-inflammatory, and differentia-
tion properties of MSCs derived from ESCs or iPSCs have been
examined by several laboratories (27, 47). However, no analysis
of the tumor-homing and anti- or protumor properties of ESC-
or iPSC-derived MSCs has been reported. We found that our
iPSC-MSCs can home to tumors with the same efficiency as BM-
MSCs, but do not promote EMT, invasion, or the stemness of
cancer cells as BM-MSCs do. BM-MSCs and cancer cells interact
through multiple mechanisms, and the molecular profiles but not
the tissue of origin of cancer cells appear to determine their
interaction with MSCs. For cancer cells producing a high level of
IL1 such as in LoVo colon cancer cells and HCC1806 breast
cancer cells, BM-MSCs are activated by tumor-derived IL1 to
produce protumor factors such as PGE2 and IL6 to promote
cancer progression (19). For cancer cells producing a low level
of IL1, such as MDA-MB-231 (widely metastatic) and MCF7
(noninvasive) breast cancer cells, (i) hyaluronan produced by
MSCs activates the CD44 pathway in cancers to induce LOX
expression and promote the EMT and invasion of cancer cells
(42); and (ii) TGFβ produced by cancer cells or tumor stromal
cells promotes expression of protumor factors such as IL6 and
SDF1 by BM-MSCs (4, 38). Intriguingly, the expression of
multiple genes related to these three pathways, including re-
ceptors for IL1 and TGFβ, IL6, SDF1, and the synthases of PGE2
and hyaluronan, as well as the production of PGE2 and hyalur-
onan, was dramatically lower in iPSC-MSCs with or without
exposure to tumor microenvironment. Together, all of the
factors may contribute to the significant decrease of protumor
potential of iPSC-MSCs. The protumor effects of MSCs happen
rapidly as indicated by significant up-regulation of pro-EMT
genes in cancer cells cocultured with BM-MSCs for 12 h (19),
suggesting that the protumor risk may compromise the efficacy
of anticancer agents delivered by MSCs and is difficult to circum-
vent by transducing MSCs with suicide genes.
The other advantage of iPSC-MSCs is that transgenes can be
inserted into safe-harbor loci of iPS cells to eliminate the risk of
insertional mutation and to guarantee the stable expression of
transgenes over prolonged expansion and differentiation (48). Sub-
sequently, MSCs can be derived from the safely engineered iPS cells.
This approach is not feasible for MSCs from bone marrow or other
tissues because of their limited expandability and because correctly
targeted clones from a single cell need to be established and then
extensively expanded for therapeutic applications.
In summary, compared with BM-MSCs, iPSC-MSCs developed
with our modified protocol have the same tumor tropism but
much less protumor potential. They can also be readily geneti-
cally engineered and the protocol can be scaled up to produce
large numbers of the cells. Hence, iPSC-MSCs prepared with the
modified protocol provide a promising alternative to BM-MSCs
for therapy of cancer patients or survivors and for other appli-
cations including bioengineering.
Materials and Methods
Detailed information is provided in SI Materials and Methods.
CY2 iPSCs were maintained and expanded in Matrigel-coated plates in the
feeder-freemTeSR1medium (Stemcell Technologies). ForMSC derivation, iPSCs
were first cultured in the mTESR1 medium supplemented with 10 μM TGFβ
inhibitor SB-431542 (44) (Sigma-Aldrich) in Matrigel-coated plates at 37 °C and
7.5% CO2 (29) and passaged at 80–90% confluence by 2 mg/mL of Dispase.
When most cells at the edge of a cell cluster became spindle-shaped in about
25 d, they were trypsinized into single cells and cultured in standard tissue-
culture plastic dishes with modified human ESC–MSC medium (30) in the
presence of SB-431542. The medium was changed daily, and the cells were
passaged at 80∼90% confluence at the ratio of 1:3 about every 3 d and
analyzed for expression of MSC surface markers by flow cytometry weekly.
When the majority of cells were positive for MSC surface markers, they were
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Fig. 5. TGFβ-SDF1 pathway in iPSC-MSCs. (A) qRT-PCR
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pho-Smad2 and phospho-Smad3 in MSCs cultured under
above conditions, normalized to GAPDH (n = 3).
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Fig. 6. The expression of HASs and TSG6 and the HA
production in MSCs and the induction of LOX in cancer
cells. (A) qRT-PCR analysis of HAS1-3 and TSG6 in MSCs
cultured alone or with LoVo cells for 3 d. (B) Enzyme im-
munoassay (EIA) analysis of HA in 6-d medium of BM-MSCs
or iPSC-MSCs at passages 5 and 15. (C) qRT-PCR analysis of
LOX in cancer cells cultured alone or with MSCs for 3 d.
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designated passage 0 iPSC-MSCs and seeded at 500 cells/cm2 in 20% (vol/vol)
FBS αMEM medium and harvested at 70–80% confluence for further
experiments.
The bone marrow MSCs (donor #7075L) were from our National Institutes
of Health-funded MSC distribution center (medicine.tamhsc.edu/irm/msc-
distribution.html) and cultured under the same conditions as iPSC-MSCs.
The multilineage differentiation of iPS-MSCs was performed using stan-
dard published conditions for BM-MSCs (48). The qRT-PCR was done as
reported (49). Telomerase activity was measured with a Quantitative Kit
(Allied Biotech, MT3010). A CFU–F culture assay and migration assays of
MSCs were performed as reported (37). Invasion assays were performed with
8-μm porous membranes coated with collagen IV. ALDH activity was exam-
ined with the ALDEFLUOR kit (Stemcell Technologies). For mammosphere
assays, breast cancer cells were transduced with CMV-copGFP and cultured
alone or with BM-MSCs or iPSC-MSCs for 3 d, isolated by FACS, and then
incubated for 7 d at 500 cells/well in ultra low-attachment 12-well plates.
All animal work was approved by the joint Scott & White and Texas A&M
Health Science Center Institutional Animal Care and Use Committee. When
s.c. xenograft models of LoVo or MDA-MB-231 cancers were established,
BM-MSCs or iPSC-MSCs transduced with CMV-copGFP lentiviruses were
injected via tail vein, and tumors were harvested 16 h later for section and
qPCR assay of CMV promoter (50). For tumor initiating and growth assay,
HCC1806 cancer cells were coinjected with BM-MSCs or iPSC-MSCs into the
fourth mammary fat pad of NOD/SCID mice, and tumors were harvested
6 wk after inoculation.
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